A newly approved combination of acalabrutinib plus venetoclax gives with newly diagnosed chronic lymphocytic leukemia (CLL) another chemotherapy-free option that is taken for a fixed period of time ...

A short film that premiered earlier this month tracks the journeys of three people who discovered a renewed commitment to living their lives to the fullest after being diagnosed with chronic ...

When Jennifer Woyach, MD, started as a resident and fellow two decades ago, patients with chronic lymphocytic leukemia (CLL) often needed to switch treatments on a regular basis as their therapies ...

First and only all-oral, fixed-duration regimen designed to provide CLL patients with the potential to experience time off treatment –– Approval expands Genentech’s fixed-duration portfolio by ...

Aging and CLL amplify fatigue, anemia, and infection risks, impacting physical activity and recovery. Tailored strategies, such as anti-inflammatory diets and strength training, can enhance resilience ...

New EORTC guidelines establish meaningful change thresholds for symptom burden, physical condition/fatigue, and worries/fears in R/R CLL or SLL patients. Thresholds help identify significant ...

MLR may be a useful marker for assessing activity and progression in chronic lymphocytic leukemia (CLL). Patients with CLL had significantly lower MLR values compared to healthy individuals, with ...

Patients who were receiving or had previously received treatment for CLL or MDS were randomly assigned (1:1) to access the MyPal digital health platform versus standard of care. The MyPal platform ...